London, England, United Kingdom In 2001 was created National Cancer Research Institute, which is appeared as Corporate Investor. The venture was found in Europe in United Kingdom. The main office of represented Corporate Investor is situated in the London.
The typical case for the fund is to invest in rounds with 1 participant. Despite the National Cancer Research Institute, startups are often financed by J. Hunt Holdings, Sun Mountain Capital. In the next rounds fund is usually obtained by National Cancer Institute SBIR Development Center.
Moreover, a startup needs to be at the age of more than 20 years to get the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline The Case Comprehensive Cancer Center (Case CCC), Agilvax Among the most successful fund investment fields, there are Hospital, Charity.
The important activity for fund was in 2018. The fund is constantly included in less than 2 deals per year. The common things for fund are deals in the range of 1 - 5 millions dollars.
Related Funds
| Fund Name | Location |
| Datiotec Electronics | - |
| Highbridge Capital Management | New York, New York, United States |
| Hudson Bay Capital Management | New York, New York, United States |
| Huimei Capital | - |
| iSGS Investment Works | Chiyoda, Japan |
| Ledstiernan | Stockholm, Stockholm County, Sweden |
| Stroud Companies | Dallas, Texas, United States |
| TASC | Chantilly, United States, Virginia |
| The Hillman Group | Cincinnati, Ohio, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
SURGE Therapeutics | $26M | 17 Oct 2022 | Cambridge, Massachusetts, United States | ||
Cartography Biosciences | $57M | 19 Jul 2022 | Foster City, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
SURGE Therapeutics | $26M | 17 Oct 2022 | Cambridge, Massachusetts, United States | ||
Cartography Biosciences | $57M | 19 Jul 2022 | Foster City, California, United States |
